MX2009011850A - Derivados de triazina, composiciones que contienen dichos derivados, y metodos para el tratamiento de cancer y enfermedades autoinmunes utilizando dichos derivados. - Google Patents

Derivados de triazina, composiciones que contienen dichos derivados, y metodos para el tratamiento de cancer y enfermedades autoinmunes utilizando dichos derivados.

Info

Publication number
MX2009011850A
MX2009011850A MX2009011850A MX2009011850A MX2009011850A MX 2009011850 A MX2009011850 A MX 2009011850A MX 2009011850 A MX2009011850 A MX 2009011850A MX 2009011850 A MX2009011850 A MX 2009011850A MX 2009011850 A MX2009011850 A MX 2009011850A
Authority
MX
Mexico
Prior art keywords
derivatives
autoimmune diseases
cancer
treatment
methods
Prior art date
Application number
MX2009011850A
Other languages
English (en)
Inventor
Christopher Penney
Lyne Gagnon
Boulos Zacharie
Brigitte Grouix
Lilianne Geerts
Shaun D Abbott
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of MX2009011850A publication Critical patent/MX2009011850A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen compuestos de la siguiente fórmula general (I): en donde X es flúor o cloro; Y es oxígeno, azufre, o un grupo amino; R es un grupo amino, hidroxilo, sulfonamida o carboxamida un análogo N-monometilo o N-dimetilo del mismo; m es un entero de 2 a 6, y n es un entero de 0 a 2. Los compuestos pueden ser utilizados para tratar ciertos cánceres y enfermedades autoinmunes. (ver fórmula (I)).
MX2009011850A 2007-04-30 2008-04-25 Derivados de triazina, composiciones que contienen dichos derivados, y metodos para el tratamiento de cancer y enfermedades autoinmunes utilizando dichos derivados. MX2009011850A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92411107P 2007-04-30 2007-04-30
PCT/CA2008/000796 WO2008131547A1 (en) 2007-04-30 2008-04-25 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives'

Publications (1)

Publication Number Publication Date
MX2009011850A true MX2009011850A (es) 2010-02-11

Family

ID=39925135

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011850A MX2009011850A (es) 2007-04-30 2008-04-25 Derivados de triazina, composiciones que contienen dichos derivados, y metodos para el tratamiento de cancer y enfermedades autoinmunes utilizando dichos derivados.

Country Status (16)

Country Link
US (1) US8258295B2 (es)
EP (1) EP2152676B1 (es)
JP (1) JP5450381B2 (es)
KR (1) KR101505215B1 (es)
CN (1) CN101679321B (es)
AU (1) AU2008243674B2 (es)
BR (1) BRPI0810921A2 (es)
CA (1) CA2684968C (es)
DK (1) DK2152676T3 (es)
ES (1) ES2415163T3 (es)
HK (1) HK1139931A1 (es)
IL (1) IL201397A (es)
MX (1) MX2009011850A (es)
PT (1) PT2152676E (es)
TW (1) TWI525080B (es)
WO (1) WO2008131547A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755394C (en) 2009-03-13 2021-10-19 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
ES2594402T3 (es) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Métodos y composiciones para trastornos relacionados con la proliferación celular
HUE033169T2 (en) * 2011-03-03 2017-11-28 Chugai Pharmaceutical Co Ltd Amino carboxylic acid modified hyaluronic acid derivative
RS57342B1 (sr) 2011-05-03 2018-08-31 Agios Pharmaceuticals Inc Aktivatori piruvat kinaze za upotrebu u terapiji
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
BR112014016805B1 (pt) * 2012-01-06 2019-07-30 Agios Pharmaceuticals, Inc. Compostos derivados de triazina, composição farmacêutica compreendendo os referidos compostos e seu uso para preparar um medicamento
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AU2013331626B2 (en) 2012-10-15 2018-08-02 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
JP6471155B2 (ja) 2013-07-11 2019-02-13 アギオス ファーマシューティカルス，インコーポレーテッド 癌の治療のためのｉｄｈ２変異体阻害剤としてのｎ，６−ビス（アリール又はヘテロアリール）−１，３，５−トリアジン−２，４−ジアミン化合物
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2014287121B2 (en) 2013-07-11 2018-11-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2919382A1 (en) * 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2942072C (en) 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
ES2704897T3 (es) 2014-09-19 2019-03-20 Forma Therapeutics Inc Derivados de piridin-2-(1H)-ona-quinolinona como inhibidores de isocitrato dehidrogenasa mutante
ES2959690T3 (es) 2015-06-11 2024-02-27 Agios Pharmaceuticals Inc Procedimientos de uso de activadores de piruvato cinasa
CN108349933A (zh) 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法
PT3362065T (pt) 2015-10-15 2024-06-21 Servier Lab Terapia de combinação compreendendo ivosidenib, citarabina e daunorubicina ou idarubicina para o tratamento de leucemia mielóide aguda
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
CA3060416A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
JP2021500327A (ja) * 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 免疫療法にｅｈｍｔ２阻害剤を使用する方法
KR101972835B1 (ko) 2018-04-27 2019-04-26 정인선 자외선 차단용 화장료 조성물.
WO2019222553A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN110511214B (zh) * 2019-06-28 2021-07-27 浙江工业大学 二胺基取代芳杂环类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519197D0 (en) 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
AU2003244463A1 (en) * 2002-02-05 2003-09-02 Yamanouchi Pharmaceutical Co., Ltd. 2,4,6-triamino-1,3,5-triazine derivative
EP1786787A4 (en) * 2004-09-03 2009-07-22 Prometic Biosciences Inc 2,4,6-TRIAMINO-S-TRIAZINE COMPOUNDS RELATED TO THE TAIL (Fc) PART OF IMMUNOGLOBULINS AND THEIR USE
JP2008540585A (ja) * 2005-05-19 2008-11-20 プロメティック・バイオサイエンスィズ・インコーポレーテッド 転移性メラノーマ及び他の癌を治療するための化合物、そのような化合物を含有する組成物、および治療方法

Also Published As

Publication number Publication date
KR101505215B1 (ko) 2015-03-23
EP2152676B1 (en) 2013-04-03
EP2152676A1 (en) 2010-02-17
DK2152676T3 (da) 2013-07-01
BRPI0810921A2 (pt) 2014-10-29
JP2010524979A (ja) 2010-07-22
CA2684968A1 (en) 2008-11-06
PT2152676E (pt) 2013-06-25
WO2008131547A1 (en) 2008-11-06
AU2008243674B2 (en) 2013-02-28
KR20100017437A (ko) 2010-02-16
ES2415163T3 (es) 2013-07-24
EP2152676A4 (en) 2010-08-25
CA2684968C (en) 2015-07-07
JP5450381B2 (ja) 2014-03-26
IL201397A0 (en) 2010-05-31
IL201397A (en) 2013-11-28
US8258295B2 (en) 2012-09-04
CN101679321B (zh) 2012-10-03
HK1139931A1 (en) 2010-09-30
TWI525080B (zh) 2016-03-11
AU2008243674A1 (en) 2008-11-06
TW200906809A (en) 2009-02-16
CN101679321A (zh) 2010-03-24
US20100129350A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
MX2009011850A (es) Derivados de triazina, composiciones que contienen dichos derivados, y metodos para el tratamiento de cancer y enfermedades autoinmunes utilizando dichos derivados.
UA94749C2 (en) Benzimidazole modulators of vr1
TW200716606A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
MY142018A (en) Thiophene derivatives as chk 1 inihibitors
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
TW200714604A (en) Substituted heterocycles and the uses thereof
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
MXPA05011166A (es) Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
TW200833675A (en) Nicotinamide derivatives
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
NO20082496L (no) Pyrazinderivater
MXPA05007462A (es) Derivados de pirrolopiridazina.
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
PL1745010T3 (pl) Podstawione pochodne cykloheksylo-1,4-diaminy
TW200621260A (en) Selected fused heterocyclics and uses thereof
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
SI1606288T1 (sl) Derivati benzensulfonamida, postopek za njihovo pripravo in njihova uporaba za zdravljenje bolečine
EA200970555A1 (ru) Трициклическое соединение и его медицинское применение
HK1107984A1 (en) Pyrrolopyridine-2-carboxylic acid amide derivativeuseful as inhibitor of glycogen phosphorylase

Legal Events

Date Code Title Description
FG Grant or registration